136 related articles for article (PubMed ID: 35311394)
1. BYL719 (alpelisib) for the treatment of PIK3CA-mutated, recurrent/advanced cervical cancer.
Bogani G; Chiappa V; Bini M; Ronzulli D; Indini A; Conca E; Raspagliesi F
Tumori; 2023 Apr; 109(2):244-248. PubMed ID: 35311394
[TBL] [Abstract][Full Text] [Related]
2. Alpelisib for
André F; Ciruelos E; Rubovszky G; Campone M; Loibl S; Rugo HS; Iwata H; Conte P; Mayer IA; Kaufman B; Yamashita T; Lu YS; Inoue K; Takahashi M; Pápai Z; Longin AS; Mills D; Wilke C; Hirawat S; Juric D;
N Engl J Med; 2019 May; 380(20):1929-1940. PubMed ID: 31091374
[TBL] [Abstract][Full Text] [Related]
3. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-Kinase α-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study.
Juric D; Rodon J; Tabernero J; Janku F; Burris HA; Schellens JHM; Middleton MR; Berlin J; Schuler M; Gil-Martin M; Rugo HS; Seggewiss-Bernhardt R; Huang A; Bootle D; Demanse D; Blumenstein L; Coughlin C; Quadt C; Baselga J
J Clin Oncol; 2018 May; 36(13):1291-1299. PubMed ID: 29401002
[TBL] [Abstract][Full Text] [Related]
5. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of Alpelisib + Fulvestrant Compared with Real-World Standard Treatment Among Patients with HR+, HER2-, PIK3CA-Mutated Breast Cancer.
Turner S; Chia S; Kanakamedala H; Hsu WC; Park J; Chandiwana D; Ridolfi A; Yu CL; Zarate JP; Rugo HS
Oncologist; 2021 Jul; 26(7):e1133-e1142. PubMed ID: 33909934
[TBL] [Abstract][Full Text] [Related]
7. FDA Approval Summary: Alpelisib Plus Fulvestrant for Patients with HR-positive, HER2-negative, PIK3CA-mutated, Advanced or Metastatic Breast Cancer.
Narayan P; Prowell TM; Gao JJ; Fernandes LL; Li E; Jiang X; Qiu J; Fan J; Song P; Yu J; Zhang X; King-Kallimanis BL; Chen W; Ricks TK; Gong Y; Wang X; Windsor K; Rhieu SY; Geiser G; Banerjee A; Chen X; Reyes Turcu F; Chatterjee DK; Pathak A; Seidman J; Ghosh S; Philip R; Goldberg KB; Kluetz PG; Tang S; Amiri-Kordestani L; Theoret MR; Pazdur R; Beaver JA
Clin Cancer Res; 2021 Apr; 27(7):1842-1849. PubMed ID: 33168657
[TBL] [Abstract][Full Text] [Related]
8. Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer.
Rugo HS; André F; Yamashita T; Cerda H; Toledano I; Stemmer SM; Jurado JC; Juric D; Mayer I; Ciruelos EM; Iwata H; Conte P; Campone M; Wilke C; Mills D; Lteif A; Miller M; Gaudenzi F; Loibl S
Ann Oncol; 2020 Aug; 31(8):1001-1010. PubMed ID: 32416251
[TBL] [Abstract][Full Text] [Related]
9. A phase III trial of alpelisib + trastuzumab ± fulvestrant versus trastuzumab + chemotherapy in HER2+
Pérez-Fidalgo JA; Criscitiello C; Carrasco E; Regan MM; Di Leo A; Ribi K; Adam V; Bedard PL
Future Oncol; 2022 Jun; 18(19):2339-2349. PubMed ID: 35465733
[TBL] [Abstract][Full Text] [Related]
10. Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: final overall survival results from SOLAR-1.
André F; Ciruelos EM; Juric D; Loibl S; Campone M; Mayer IA; Rubovszky G; Yamashita T; Kaufman B; Lu YS; Inoue K; Pápai Z; Takahashi M; Ghaznawi F; Mills D; Kaper M; Miller M; Conte PF; Iwata H; Rugo HS
Ann Oncol; 2021 Feb; 32(2):208-217. PubMed ID: 33246021
[TBL] [Abstract][Full Text] [Related]
11. Dermatologic adverse events related to the PI3Kα inhibitor alpelisib (BYL719) in patients with breast cancer.
Wang DG; Barrios DM; Blinder VS; Bromberg JF; Drullinsky PR; Funt SA; Jhaveri KL; Lake DE; Lyons T; Modi S; Razavi P; Sidel M; Traina TA; Vahdat LT; Lacouture ME
Breast Cancer Res Treat; 2020 Aug; 183(1):227-237. PubMed ID: 32613539
[TBL] [Abstract][Full Text] [Related]
12. Targeting HER2-mutant metastatic cervical cancer with neratinib: Final results from the phase 2 SUMMIT basket trial.
Friedman CF; D'Souza A; Bello Roufai D; Tinker AV; de Miguel M; Gambardella V; Goldman J; Loi S; Melisko ME; Oaknin A; Spanggaard I; Shapiro GI; ElNaggar AC; Panni S; Ravichandran V; Frazier AL; DiPrimeo D; Eli LD; Solit DB
Gynecol Oncol; 2024 Feb; 181():162-169. PubMed ID: 38211393
[TBL] [Abstract][Full Text] [Related]
13. Alpelisib Efficacy in Hormone Receptor-Positive HER2-Negative PIK3CA-Mutant Advanced Breast Cancer Post-Everolimus Treatment.
Raphael A; Salmon-Divon M; Epstein J; Zahavi T; Sonnenblick A; Shachar SS
Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292649
[TBL] [Abstract][Full Text] [Related]
14. Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.
Wei Y; Lin S; Zhi W; Chu T; Liu B; Peng T; Xu M; Ding W; Cao C; Wu P
J Med Virol; 2023 Mar; 95(3):e28656. PubMed ID: 36905114
[TBL] [Abstract][Full Text] [Related]
15. The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer.
Pignata S; Scambia G; Lorusso D; De Giorgi U; Nicoletto MO; Lauria R; Mosconi AM; Sacco C; Omarini C; Tagliaferri P; Ferrandina G; Cinieri S; Savarese A; Valabrega G; Pisano C; Salutari V; Raspagliesi F; Kopf B; Cecere SC; Amadio G; Maltese G; Di Napoli M; Greggi S; Signoriello S; Daniele G; Sacco A; Losito S; Normanno N; Perrone F; Gallo C; Piccirillo MC;
Gynecol Oncol; 2019 Jun; 153(3):535-540. PubMed ID: 30979589
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Coleman RL; Lorusso D; Gennigens C; González-Martín A; Randall L; Cibula D; Lund B; Woelber L; Pignata S; Forget F; Redondo A; Vindeløv SD; Chen M; Harris JR; Smith M; Nicacio LV; Teng MSL; Laenen A; Rangwala R; Manso L; Mirza M; Monk BJ; Vergote I;
Lancet Oncol; 2021 May; 22(5):609-619. PubMed ID: 33845034
[TBL] [Abstract][Full Text] [Related]
17. Which Is the Most Appropriate PI3K Inhibitor for Breast Cancer Patients with or without PIK3CA Status Mutant? A Systematic Review and Network Meta-Analysis.
Wang S; Liu M; Lian S; Liu N; Zhang G; Zhao Q; Zhang Y; Jian L
Biomed Res Int; 2020; 2020():7451576. PubMed ID: 33376736
[TBL] [Abstract][Full Text] [Related]
18. Results from a single arm, single stage phase II trial of trametinib and GSK2141795 in persistent or recurrent cervical cancer.
Liu JF; Gray KP; Wright AA; Campos S; Konstantinopoulos PA; Peralta A; MacNeill K; Morrissey S; Whalen C; Dillon D; Matulonis UA
Gynecol Oncol; 2019 Jul; 154(1):95-101. PubMed ID: 31118140
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancer.
Friedman CF; Snyder Charen A; Zhou Q; Carducci MA; Buckley De Meritens A; Corr BR; Fu S; Hollmann TJ; Iasonos A; Konner JA; Konstantinopoulos PA; Modesitt SC; Sharon E; Aghajanian C; Zamarin D
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004542
[TBL] [Abstract][Full Text] [Related]
20. Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Passarelli A; Carbone V; Pignata S; Mazzeo R; Lorusso D; Scambia G; Canova S; Di Palma T; Tasca G; Mantiero M; Naglieri E; Andreetta C; Rauso M; Brunetti AE; Laera L; Abeni C; Scandurra G; Gambaro AR; Pastore A; Bengala C; Gunnellini M; Farolfi A; Spinello M; Bartoletti M
Gynecol Oncol; 2024 Mar; 183():61-67. PubMed ID: 38518529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
